UY36192A - Análogos de pridopidina, su preparación y uso - Google Patents
Análogos de pridopidina, su preparación y usoInfo
- Publication number
- UY36192A UY36192A UY0001036192A UY36192A UY36192A UY 36192 A UY36192 A UY 36192A UY 0001036192 A UY0001036192 A UY 0001036192A UY 36192 A UY36192 A UY 36192A UY 36192 A UY36192 A UY 36192A
- Authority
- UY
- Uruguay
- Prior art keywords
- phenyl
- pridopidine
- methylsulfonyl
- provides
- pharmacological
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8872—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample impurities
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Spectroscopy & Molecular Physics (AREA)
Abstract
Esta invención provee un compuesto aislado que tiene la siguiente estructura: una sal del mismo. La invención también provee un proceso para preparar 4-(3-(metilsulfonil)fenil)- 1-propilpiperidin-4-ol, 1-(3,3-bis(3-(metilsulfonil)fenil)propil)-4-(3- (metilsulfonil)fenil)piperidona, 1,4-bis((3-(1-propilpiperidin-4-il)fenil)sulfonil)butano, (3R,4S)-4-(3-(metilsulfonil)fenil)-1-propilpiperidin-3-ol, 1-óxido de 4-(3- (metilsulfonil)fenil)-1-propilpiperidina, 1-(2-metilpentil)-4-(3- (metilsulfonil)fenil)piperidina, 4-(3-(metilsulfinil)fenil)-1-propil-1,2,3,6-tetrahidropiridina, y 4-(3-(metilsulfonil)fenil)-1-propil-1,2,3,6-tetrahidropiridina. Esta invención también provee una impureza o una sal de la misma para su uso como estándar de referencia para detectar trazas de la impureza en una composición farmacéutica que comprende pridopidina o una sal farmacéuticamente aceptable de la misma. Esta invención además provee un proceso para producir un producto farmacológico de pridopidina que comprende obtener una 5 sustancia farmacológica de pridopidina y mezclar la sustancia farmacológica de pridopidina con excipientes adecuados para dar el producto farmacológico de pridopidina. Esta invención también provee un proceso para producir un producto farmacológico de pridopidina. Esta invención también provee un proceso de distribución de un producto farmacológico de pridopidina
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462019337P | 2014-06-30 | 2014-06-30 | |
| US201462076436P | 2014-11-06 | 2014-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36192A true UY36192A (es) | 2016-01-29 |
Family
ID=54929343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036192A UY36192A (es) | 2014-06-30 | 2015-06-26 | Análogos de pridopidina, su preparación y uso |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10130621B2 (es) |
| EP (2) | EP4049998A1 (es) |
| JP (2) | JP6800842B2 (es) |
| CN (2) | CN106456618A (es) |
| AU (1) | AU2015284385B2 (es) |
| BR (1) | BR112016030968B1 (es) |
| CA (1) | CA2951494C (es) |
| DK (1) | DK3160470T3 (es) |
| EA (1) | EA201790101A1 (es) |
| ES (1) | ES2927888T3 (es) |
| HK (1) | HK1231406A1 (es) |
| HU (1) | HUE060242T2 (es) |
| IL (2) | IL249601B (es) |
| MX (1) | MX2016017332A (es) |
| PL (1) | PL3160470T3 (es) |
| TW (1) | TW201613859A (es) |
| UY (1) | UY36192A (es) |
| WO (1) | WO2016003919A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| US11090297B2 (en) * | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| HUE054783T2 (hu) | 2013-06-21 | 2021-09-28 | Prilenia Neurotherapeutics Ltd | Pridopidin Huntington-kór kezelésében |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP3590512A1 (en) | 2015-02-25 | 2020-01-08 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat epilepsy |
| WO2023062632A1 (en) * | 2021-10-11 | 2023-04-20 | Prilenia Neurotherapeutics Ltd. | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| ES2979123T3 (es) | 2016-02-24 | 2024-09-24 | Prilenia Neurotherapeutics Ltd | Tratamiento de una enfermedad ocular neurodegenerativa usando pridopidina |
| JP6912574B2 (ja) | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
| EP3503890A4 (en) | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| ES2938546T3 (es) | 2017-08-14 | 2023-04-12 | Prilenia Neurotherapeutics Ltd | Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina |
| CN111278431A (zh) | 2017-08-30 | 2020-06-12 | 普瑞尼亚神经治疗有限公司 | 普利多匹定的高浓度剂型 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| BR112021018262A2 (pt) * | 2019-03-15 | 2022-02-01 | Prilenia Neurotherapeutics Ltd | Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina |
| BR112021024744A2 (pt) * | 2019-06-12 | 2022-03-22 | Prilenia Neurotherapeutics Ltd | Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington |
| JP2023534095A (ja) * | 2020-05-04 | 2023-08-08 | プリレニア ニューロセラピューティクス リミテッド | 選択的ｓ１ｒアゴニストを使用するウイルス感染、疾患、又は障害の治療 |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| JP2023545846A (ja) * | 2020-10-20 | 2023-10-31 | プリレニア ニューロセラピューティクス リミテッド | 不安及び抑うつを治療するためのプリドピジンまたはその類似体の使用 |
| WO2022219637A1 (en) * | 2021-04-14 | 2022-10-20 | Prilenia Neurotherapeutics Ltd. | Treatment of prodromal huntington disease |
| CN114716391B (zh) * | 2022-04-24 | 2023-12-12 | 杭州仟源保灵药业有限公司 | 一种醋甲唑胺杂质及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6472736A (en) | 1987-09-14 | 1989-03-17 | Toshiba Corp | Mri apparatus |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| MXPA06008197A (es) * | 2004-01-21 | 2007-04-02 | Teva Pharma | Proceso para la preparacion de clorhidrato de valaciclovir. |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| JP2008501748A (ja) * | 2004-06-08 | 2008-01-24 | ニューロサーチ スウェーデン アクチボラゲット | ドーパミン神経伝達のモジュレーターとしての新規な置換されたピペリジン |
| EP1692134A2 (en) * | 2004-09-04 | 2006-08-23 | Teva Pharmaceutical Industries, Inc. | A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard |
| HUE029790T2 (hu) * | 2004-10-13 | 2017-04-28 | Teva Pharmaceuticals Int Gmbh | Eljárás 4-(3-metánszulfonil-fenil)-l-N-propil-piperidin elõállítására |
| CA2584833A1 (en) * | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines |
| KR20090108739A (ko) * | 2005-01-03 | 2009-10-16 | 테바 파마슈티컬 인더스트리즈 리미티드 | 불순물의 양이 감소된 올메사탄 메독소밀 |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| EP1961742A1 (en) | 2007-02-22 | 2008-08-27 | Novartis AG | compounds of formula (I) as serine protease inhibitors |
| CN101711236B (zh) * | 2007-04-12 | 2012-10-31 | Nsab神经研究瑞典公司分公司 | 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 |
| WO2008155357A2 (en) * | 2007-06-18 | 2008-12-24 | A. Carlsson Research Ab | Use of dopamine stabilizers |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| US20130216856A1 (en) | 2010-07-02 | 2013-08-22 | Marco Burtchen | Mechanical component and method of surface hardening |
| US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| BR112014005389A8 (pt) | 2011-09-07 | 2018-04-03 | Ivax Int Gmbh | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| EA027748B1 (ru) | 2012-04-04 | 2017-08-31 | Тева Фармасьютикалз Интернэшнл Гмбх | Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения |
| CA2884781A1 (en) | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
| HUE054783T2 (hu) | 2013-06-21 | 2021-09-28 | Prilenia Neurotherapeutics Ltd | Pridopidin Huntington-kór kezelésében |
| CN106170287A (zh) | 2014-01-22 | 2016-11-30 | 梯瓦制药国际有限责任公司 | 改进释放的普利多匹定制剂 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP3590512A1 (en) | 2015-02-25 | 2020-01-08 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat epilepsy |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| US20170020854A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
-
2015
- 2015-06-23 TW TW104120197A patent/TW201613859A/zh unknown
- 2015-06-26 UY UY0001036192A patent/UY36192A/es not_active Application Discontinuation
- 2015-06-29 EA EA201790101A patent/EA201790101A1/ru unknown
- 2015-06-29 EP EP22165235.7A patent/EP4049998A1/en active Pending
- 2015-06-29 BR BR112016030968-5A patent/BR112016030968B1/pt active IP Right Grant
- 2015-06-29 PL PL15814023.6T patent/PL3160470T3/pl unknown
- 2015-06-29 JP JP2017520772A patent/JP6800842B2/ja active Active
- 2015-06-29 EP EP15814023.6A patent/EP3160470B1/en active Active
- 2015-06-29 WO PCT/US2015/038349 patent/WO2016003919A1/en active Application Filing
- 2015-06-29 HU HUE15814023A patent/HUE060242T2/hu unknown
- 2015-06-29 MX MX2016017332A patent/MX2016017332A/es unknown
- 2015-06-29 CA CA2951494A patent/CA2951494C/en active Active
- 2015-06-29 DK DK15814023.6T patent/DK3160470T3/da active
- 2015-06-29 AU AU2015284385A patent/AU2015284385B2/en active Active
- 2015-06-29 ES ES15814023T patent/ES2927888T3/es active Active
- 2015-06-29 CN CN201580035520.9A patent/CN106456618A/zh active Pending
- 2015-06-29 CN CN202110715595.9A patent/CN113511997A/zh active Pending
- 2015-06-29 US US14/754,339 patent/US10130621B2/en active Active
-
2016
- 2016-12-15 IL IL249601A patent/IL249601B/en active IP Right Grant
-
2017
- 2017-05-23 HK HK17105207.9A patent/HK1231406A1/zh unknown
-
2018
- 2018-10-03 US US16/150,977 patent/US10406145B2/en active Active
-
2019
- 2019-08-08 US US16/535,107 patent/US11141412B2/en active Active
-
2020
- 2020-01-28 IL IL272306A patent/IL272306B/en active IP Right Grant
- 2020-04-24 JP JP2020077160A patent/JP7035108B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY36192A (es) | Análogos de pridopidina, su preparación y uso | |
| AR125321A2 (es) | Compuesto cristalino, método de preparación y composición que lo comprende | |
| TN2018000410A1 (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| EA033497B1 (ru) | 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1 | |
| CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
| DOP2017000048A (es) | Compuestos aminopirimidinilo como inhibidores de jak. | |
| TN2016000268A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2. | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| CL2008003480A1 (es) | Compuestos derivados de amino-pirimidina, con propiedades inmunomoduladoras y que actuan a traves de tlr7; proceso para preparar los compuestos; compuestos intermediarios; composicion y combinacion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos | |
| BR112017004448A2 (pt) | uso de agente de reforço de receptor gabaa na preparação de medicamento sedativo e anestésico | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| MY198113A (en) | Piperidine cxcr7 receptor modulators | |
| DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| WO2016100349A3 (en) | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists | |
| AR090073A1 (es) | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos | |
| AR090975A1 (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| BR112018072063A2 (pt) | compostos de pirimidinona fundida substituída | |
| AR101037A1 (es) | Análogos de pridopidina, su preparación y uso | |
| PH12018500014A1 (en) | Total synthesis of shishijimicin a and analogs thereof | |
| CY1119701T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει υδροχλωρικη βαρδεναφιλη | |
| WO2015186139A3 (en) | Novel polymorphs of tenofovir disoproxil oxalate and process for preparation of the same | |
| EA201992644A1 (ru) | Твердые фармацевтические композиции на основе дабигатрана этексилата для перорального применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20220629 |